Table 1.
Reported cases of COVID-19 pneumonia with severe immune thrombocytopenia.
| Author | Age /Sex |
Severity of COVID-19 pneumoniaa | CS | Heparin | Time from COVID-19 onset to immune thrombocytopenia diagnosis | Severity of immune thrombocytopeniab |
Treatment of immune thrombocytopenia |
Outcome |
|---|---|---|---|---|---|---|---|---|
| Martincic [10] | 48/M | critical | unused | used | 12days | severe (gastrointestinal bleeding) | CS, IVIG | Alive |
| Deruelle [11] | 41/M | critical | unused | used | 27days | severe (tracheal hemorrhage) | CS, IVIG | Alive |
| Levesque [12] | 53/M | critical | unused | used | 27days | severe (intracranial bleeding) | CS, IVIG, PT romiplostim、vincristine | Alive |
| Zulfigar [13] | 65/F | severe | unused | used | 4days | severe (intracranial bleeding) | CS, IVIG, PT | N.D. |
| Bomhof [14] | 67/M | critical | unused | used | 21days | severe (intracranial bleeding) | PT | Dead |
| Mahevas [15] | 74/M | severe | N.D. | N.D. | 12days | severe (gastrointestinal bleeding) | CS | Alive |
| Mahevas [15] | 66/F | severe | N.D. | N.D. | 8days | severe (intracranial bleeding) | CS, IVIG, eltrombopag | Alive |
| Our case | 72/M | severe | used | used | 47days | severe (diffuse alveolar hemorrhage) | CS | Alive |
CS, corticosteroid; PT, platelet transfusion; IVIG, intravenous immunoglobulin.
a
Severity of COVID-19 is based on NIH COVID-19 treatment guidelines.
b
Severity of immune thrombocytopenia is based onan international working group report of immune thrombocytopenic purpura of adults.